Targeting SARS-CoV-2 differently
German structural biologists have identified seven compounds that neutralise SARS-CoV-2 by targeting Mpro, the virus main protease.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
miRNAs unmask vulnerability in breast cancer stem cells
/in News/by Thomas GabrielczykResearchers in Italy have identified a pair of microRNA molecules, miR-146A and miR-, help maintain a population of breast cancer stem cells
Janssen to pledge COVID-19 vaccine to African Union
/in News/by Thomas GabrielczykJohnson & Johnson subsidiary Janssen Pharmaceutica NV has confirmed to deliver 220 million doses of its COVID-19 vaccine to the African Vaccine Acquisition Trust (AVAT).
Bispecific IgG switch off SARS-CoV-2 escape variants
/in News/by Thomas GabrielczykA bispecific antibody designed by a Swiss-Czech research team suppressed viral escape of SARS-CoV-2 variants in animals.
Step Pharma SAS raises 35m in Series B
/in News/by Thomas GabrielczykKurma Partners-founded Step Pharma has baged 35m in a Series B financing to advance its blood cancer lead STP938.
AZD1222 claims 79% effecacy in pivotal US study
/in News/by Thomas GabrielczykFollowing assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
/in News/by Thomas GabrielczykOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Novel COVID antibody enters clinical testing
/in News/by Thomas GabrielczykGerman CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days.
B.1.1.7 variant associated with higher mortality
/in News/by Thomas GabrielczykThe B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche in take-over deal with GenMark Diagnostics
/in News/by Thomas GabrielczykRoche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.